Skip to content
Home/Companies/Healthcare / Biotech/Innate Pharma

Innate Pharma

Healthcare / Biotech·France·Exited 2006·Held 6yr
Entry
2000
Hold
6yr
Exit
2006

Who owns Innate Pharma?

Innate Pharma was owned by Sofinnova Partners through Sofinnova Capital VI (2008 vintage) from 2000 to 2006, exited via IPO.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VI · 2008 · Life Sciences VC

Key facts

HQFrance
SectorHealthcare / Biotech
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2006

More from Sofinnova Capital VI

Other portfolio companies in the same fund.

ABIONYX Pharma
Exited 2020
BiotechFrance· 2010
DBV
Exited 2014
BiotechFrance· 2010
Omthera Pharmaceuticals
Exited 2013
BiotechUS· 2010
to
Ablynx NV
Exited 2018
BiotechBelgium· 2008
to
Addex Therapeutics
Exited 2012
BiotechSwitzerland· 2008
Movetis
Exited 2010
BiotechBelgium· 2008
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Innate Pharma

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Innate Pharma?

0 strategic and 120financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Innate Pharma.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue